Zhu Ke, Xu Aiqun, Xia Wanli, Li Pulin, Zhang Binbin, Jiang Huihui, Zhou Sijing, Wang Ran
Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Department of General Medicine, Hefei Second People's Hospital, Hefei, China.
Front Oncol. 2021 Mar 11;11:567762. doi: 10.3389/fonc.2021.567762. eCollection 2021.
Lung cancer is the leading cause of cancer-related death worldwide and has a high incidence rate. N-Acetyltransferase 2 (NAT2) is a polymorphic xenobiotic enzyme, which can catalyze N-acetylation and O-acetylation of various carcinogens such as aromatic, heterocyclic amines and hydrazines. At present, many studies have explored the effects of NAT2 polymorphism on lung cancer, but we found inconsistent results. We researched 18 published studies, involving 4,016 patients and 5,469 controls, to more accurately assess the effects of NAT2 polymorphism on lung cancer risk and to investigate whether smoking is associated. We used STATA software to analyze the extracted data and used STATA for subgroup analysis, sensitivity analysis, and to perform publication bias tests. To determine the correlation, we used the crude odds ratio (ORs) with 95% confidence interval (CIs). Our study was prospectively registered in PROSPERO (CRD42020159737). The odds ratio was 1.53 (95% CI: 1.211.95, I² = 45.2%, P=0.104) for the NAT2 slow + intermediate phenotype rapid phenotype. The results suggested that people with NAT2 non-rapid (slow + intermediate) phenotype have a significantly increased risk of lung cancer. In addition, NAT2 rapid phenotype was significantly associated with reduced risk of lung cancer, compared with slow phenotype or intermediate phenotype (slow phenotype . rapid phenotype: OR: 1.61, 95% CI: 1.07-2.42, I²= 50%, P= 0.075; intermediate phenotype . rapid phenotype: OR: 1.47, 95% CI: 1.15-1.88, I²= 40.3%, P= 0.137).
肺癌是全球癌症相关死亡的主要原因，发病率很高。N-乙酰基转移酶2（NAT2）是一种多态性外源性生物酶，可催化各种致癌物（如芳香胺、杂环胺和肼）的N-乙酰化和O-乙酰化。目前，许多研究探讨了NAT2多态性对肺癌的影响，但我们发现结果并不一致。我们检索了18项已发表的研究，涉及4016例患者和5469例对照，以更准确地评估NAT2多态性对肺癌风险的影响，并调查吸烟是否与之相关。我们使用STATA软件分析提取的数据，并使用STATA进行亚组分析、敏感性分析和发表偏倚检验。为了确定相关性，我们使用了具有95%置信区间（CI）的粗比值比（OR）。我们的研究已在PROSPERO（CRD42020159737）上进行了前瞻性注册。NAT2慢+中间表型与快速表型的比值比为1.53（95%CI：1.21-1.95，I² = 45.2%，P = 0.104）。结果表明，NAT2非快速（慢+中间）表型的人患肺癌的风险显著增加。此外，与慢表型或中间表型相比，NAT2快速表型与肺癌风险降低显著相关（慢表型与快速表型：OR：1.61，95%CI：1.07-2.42，I² = 50%，P = 0.075；中间表型与快速表型：OR：1.47，95%CI：1.15-1.88，I² = 40.3%，P = 0.137）。
